Foghorn Therapeutics Unveils Preclinical Data for Key Oncology Programs at AACR 2026
Event summary
- Foghorn Therapeutics will present preclinical data for its selective SMARCA2 inhibitor FHD-909 (LY4050784) and other degrader programs at the 2026 AACR Annual Meeting.
- FHD-909 data suggests potential expansion opportunities in combination with anti-PD-1 antibodies for SMARCA4-mutant lung cancer.
- Preclinical characterization of FHT-171, a selective CBP degrader, shows promise in ER+ breast cancer.
- Progress reported across selective EP300 degrader in hematological malignancies and selective ARID1B degrader in ARID1A-mutant tumors.
The big picture
Foghorn Therapeutics is positioning itself as a leader in targeting chromatin regulatory proteins, a critical area in oncology with significant unmet needs. The company's focus on selective inhibitors and degraders aligns with the industry trend towards precision medicine, aiming to correct abnormal gene expression in cancer. The upcoming AACR presentations will be key in validating the company's scientific approach and pipeline potential.
What we're watching
- Clinical Translation
- How the preclinical data for FHD-909 will translate into clinical outcomes, particularly in combination therapies.
- Pipeline Progression
- The pace at which Foghorn can advance its degrader programs through preclinical and into clinical stages.
- Competitive Positioning
- Whether Foghorn can differentiate its chromatin regulatory protein targets in the crowded oncology space.
Related topics